{"name":"Aviceda Therapeutics, Inc.","slug":"aviceda-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AVD-104","genericName":"AVD-104","slug":"avd-104","indication":"Other","status":"phase_2"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Avacincaptad","genericName":"Avacincaptad","slug":"avacincaptad","indication":"Geographic atrophy secondary to age-related macular degeneration","status":"marketed"}]}],"pipeline":[{"name":"AVD-104","genericName":"AVD-104","slug":"avd-104","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Avacincaptad","genericName":"Avacincaptad","slug":"avacincaptad","phase":"marketed","mechanism":"Complement C5","indications":["Geographic atrophy secondary to age-related macular degeneration"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOZkpoOHZJTjRkbXVuWFhqZXVEMWM0b2pzaHQ3dTFZQWFQR3YxUVVzLU8ya2JEbEhKVjEtenMwb20xSDNfRE1tMTd0Qlg0bGROVmdyVURTQjM0STg3Q195aC1zVjJSbnFlR3FOd29PTm8ybGNGWGpkTFd0WERhek1scDEtc1JmUDdkVWxGendmd1Nnbklv?oc=5","date":"2026-03-12","type":"regulatory","source":"openPR.com","summary":"Diabetic Macular Edema Treatment Pipeline Shows Strong - openPR.com","headline":"Diabetic Macular Edema Treatment Pipeline Shows Strong","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOSDlnYTVTajJZOWp2ZGV1QjZlQlpEeURHQm5JY2c2UDlnMzN0NTZxY0RRUEdEWGR1dnVJYTNOUTBQZURUS2FfNnplTThiVzdrUWNMN0VhaFlUUGtGYkFLemZtNVgwLUd1ZTVZb1ctdTlJaGtSSVlUeWFyQ3VmTk1ZN0N3bUJxXy1KRV9zbUxJQmNDd1VNSXI3c0J5NVJJN2hZRkxOVF9n?oc=5","date":"2025-12-15","type":"trial","source":"Fierce Biotech","summary":"Aviceda geographic atrophy hopeful fails to top Astellas' med in phase 2 - Fierce Biotech","headline":"Aviceda geographic atrophy hopeful fails to top Astellas' med in phase 2","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy Market to Surge Significantly During the - GlobeNewswire","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOME5PenpCcHNuVTZkT1kwblVkbldBcjMydHdFWnlUU3JLaWh1ai1mbi1rZlpNcG93b3Y4dTYxYWhCRmhFQ2l2QmxDWWYtdFNJQjcwc251Mi1NZUtPV1ZxLUlOUmVqRmVFcjQ5dXFWQU9ucmVQWnlzTHNoMkFxMkFuTFFSQktIcFdYd1E?oc=5","date":"2025-11-17","type":"pipeline","source":"Yahoo Finance","summary":"Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight - Yahoo Finance","headline":"Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expandin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOYlE1bDB1YnJCNjQ0QVBTMWdxb1ZwXzhLTFQ5ZHhEbWxWbnF1U2g1OGFydDlWYW1Pb1I2WklXdzNXZkhSSmFCUGVEX3ZWemg3VmhoSXd6WlY3X3JqZHpLYnZGY3JQWVdKOEcybWQzRHhyamFDSDJBckcxYngyd3hTS1kza0RqbXR2SVR2dnkyOGZWQ0ZXVzV0bXpzcF9UenFvRmFVQnlZU3NuaHlEcG10SHY0Z0pxOG1rdjQ2WGpSZnAxYWFFQjBENkZwNHMxc190S1dNdGE2Y3ZlZ21fVWV2OTJtX2NSaEd5Vm1nLTBpMGpsRnRnVFVHNmRNVUZ5NkhvX2pXaXlDQ0wwckEwR2c?oc=5","date":"2025-04-09","type":"pipeline","source":"Business Wire","summary":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire","headline":"Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Dire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxPaUxZOGo4Ri1ZYWUyRl9zTDhmaHNTLTdGSm9aWERITFJQR3ZVa3JaLWVfQlhEd1pMclBoMnQtZUtVRlZTTFdEZlpDSkFSOU0xTjJNQVU2MlRPNHJnaXRyazZGMHA3LVE3VUJ6TTN5S3F0dDZhd0VSaE9jQkVMYk9CbG80VEc3eDYwdFhTNXIxT0dQcXhhV3pyVm4yNl9JMVg1QVhSSHRpZjBlQ0hrejUzU05JVFU1cXJ6LWtuUnZhTVNuTHJST2tIaHB1aWVHMGl1b1JXN3hNaXBEN19SajlmNjV1ZEZSVkJ0UjR5OTdKc21wTTJzWVRSNEZmQm9OOUJBYXdMMFZCTFRFNnBOQXdjWXVYZ2hhRFR2Q0E?oc=5","date":"2025-04-01","type":"trial","source":"Business Wire","summary":"Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation - Business Wire","headline":"Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPdTFlbDdiTXVOWE0taXd6dU5veXVUMmhyWmhaWkFJblBIamYzSGY3dUhsLXVOZ3NEYkZsTmtIZ3RCVm8tb3R0RjB6SUtZeVltR21NTXRuR3EtdlFGRHhGYkNuVS0xT1F4bXBjd2ZVYUEwSkR4REhudy1ZYTFOS3B6ZlJnYUZhb2lzeFYyMUhOXy0xOUd2X1dsbHluOUPSAaIBQVVfeXFMTm5WTnJPeU13R1NSaHh3M3FyT1REUjRfaUpBNjEwNzVfSEEzLTlQUm1QWmVNbU95XzZubjlJdUxHNGFRdWJ1eTQzWnNjbGhUVUc3N0x0azhUUkFXVG90SjVkcVJ0RVRSRktHUDd5MWRnWGxKV0VMS1hNMzhib3Vud3M3NHl3ZTlCNzVHTUpCQjdOa3Fhc0lkU2w2LVRUTVpFRi13?oc=5","date":"2025-02-07","type":"deal","source":"Express Pharma","summary":"Pharma M&A and venture capital deals reach $33.7 billion in Jan 2025 - Express Pharma","headline":"Pharma M&A and venture capital deals reach $33.7 billion in Jan 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNSF8xbF9kOFk3TzBRUzVFNVNFWGRLVFk1VUpiTXVfYWdUN3RyR2NMa1R3QTl1NnhjS0RpME84bHRzbmNieHhvd2JrZjlxazdZSDNHcVFTb3h2YW1jaEpSMjR6cGlSQldjSnJaVkE0NUNyY1FRRElpR1FUNU1Zenl5YVFSUUhmNTdOcmllbEVDZk5IV2xkbTBmcXlyUEh5eW5IZjZ2U2RhRVdSX0FqdzJ1NnNCN1dHYmJNRHk0NDNvNlNiZ0dfSjd5Z2VTaUpZb0dhU3V4a2JJel9RbllGY1E2b2c1d2tWdVh1elpFcW5WOUJfaF9tU3FLaDJ6c2UzUQ?oc=5","date":"2025-01-23","type":"trial","source":"PR Newswire","summary":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - PR Newswire","headline":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNcXpabWtnRXlGOXU4LTRtUUUwRm1lVnozd1RBcE9JSjluX0FZdTZUT0xCd0x3aVpfNkVmdXZtRjJ2LVhrVzhYVHg1OGxSaE9ieWNrbkhiLXd1SkRmZjJDaE03YzNmV3ZBdVRoQnVQdWF2Tjl1TXViN3BGam0xUi1zNDlScHRQWUswTVdvb3VNWDljMDNGMllPcXhIUDhyS3VFR1JsMm8tVmlYRFpSNmFCZ0lxZUNSY2lJc1Jia01KVFZaLU1MVkhQYkZYbE5GNmdhMFAzN2E2S3R2d2tYczJBRXpYb0EyaXBXbWdRZHNBQkt4cjMyRXBmRWViWmUtLWU0Mm4tdnZVTHlwY29ROERyV1RsWUwxWHpRcTA3dmhudG5XQnY1TnpMOTRWRDVjekQwZ2pGZ2ZFbw?oc=5","date":"2025-01-07","type":"trial","source":"Business Wire","summary":"Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials - Business Wire","headline":"Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geogr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOQmpzMWdpQkFqUWJVVndlQ3BocjZOcklaRTN2MExpakxnTGVqRm13NS1NLXZGVVVqX0VWdzJMZV9oR1g4WEdaejloWk16ODRybWtIUXp5Yjh4MTFRT2xLM1R4OTRpQmpPZ3NQMkdmN2VmUnNuRlBEM3ItS1daSnM5aVpxWkEwTG5fUjd1WWVuejUtaVpYRXRPSW5NUHFmVG9JRllaRUNjVHU?oc=5","date":"2023-05-17","type":"pipeline","source":"modernretina.com","summary":"Aviceda Therapeutics appoints Patrick Johnson to its board of directors - modernretina.com","headline":"Aviceda Therapeutics appoints Patrick Johnson to its board of directors","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}